Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RE104 in Generalized Anxiety Disorder
NCT07489651Phase 2Recruiting
- Sponsor
- Reunion Neuroscience
- Start
- Apr 2026
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
A Phase 2 trial of RE104 in generalized anxiety disorder (GAD), sponsored by Reunion Neuroscience. Started Apr 2026; status: recruiting.
02
Drugs
RE104
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT07489651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07489651.